Understand we're in very, very nascent stages but just -- I know that retail is muted and you gave some of the factors in your press release and prepared remarks as to why guidance has come down, but just a general first sort of three or four weeks of cannabis 2.0 from a logistical standpoint, how that's been going. Aphria is well-positioned for long-term sustainable growth as we continue to manage the controllable aspects of our business,” stated Aphria CFO Carl Merton. This site uses cookies to provide you with a great user experience. And finally, Plant Positivity, our social impact platform, the champions plants and the incredible power they have in overall well-being as well as looking to improve access to green spaces for communities. Is there going to be a gradual decline because I imagine we're going to see more substantial decreases in that segment given your new guidance. As I said, we have a very interesting and we are looking at multiple opportunities for the US, just not around CBD, around other products that will complement cannabis and that's something that we will be focused on. I'd like to thank my leadership team, my Board and our associates around the world for all their help getting us to where we are today and their continued dedication to moving Aphria forward. In summary, at Aphria we have differentiated brands, product innovation, greenhouse space, cultivation expertise, extraction capacity and automation technology to position us for success. Aphria Inc (NYSE:APHA) Q2 2020 Earnings Conference Call - Final Transcript Good morning. Together, we all appreciate the hard work and dedication that has propelled us forward and will continue our future success is on horizon. Stock Advisor launched in February of 2002. focused on uncovering paradigm-shifting marijuana stocks and reporting on the evolving cannabis value chain. Aphria Inc (NASDAQ:APHA)Q2 2020 Earnings CallJan 14, 2020, 8:00 a.m. Aphria Reports Q2 Earnings and Revised 2020 Guidance, Adjusted EBITDA Soars 155% + APHA Stock Chart Review, Aphria (TSX: APHA) (NYSE: APHA) (FRA: 10E), Inverse Head and Shoulders bottom pattern, Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1), the simple formula in our previous article, Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week, https://www.youtube.com/watch?v=uzN_jK7U7g8, Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week, ‘Psychedelic Capitalism’ a New Concern as the Psychedelics Industry Takes Shape, The company’s total adult-use and medical cannabis. Brett Michael Hundley -- Seaport Global Securities LLC -- Analyst. Click to subscribe to real-time analytics on APHA, Now read: Don't Bet On A Marijuana Turnaround In 2020 », Don't Bet On A Marijuana Turnaround In 2020 ». We are increasingly connecting with consumers for our medical and adult-use brand positioning and innovation to drive growth. My first question was with respect to CC Pharma and the distribution revenue. At Aphria, we strive to be better in all that we do as an industry leader. The market expects Aphria Inc. (APHA) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended November 2019. In the US, we are focused on building strategic partnership and alliances for growth with an emphasis on industries that aren't necessarily attached to, but rather complement cannabis until medical cannabis is fully legalized. Please go ahead. In our GMP export and white label opportunities, we are pleased to have received confirmation of compliance with the requirements of the EU-GMP from Maltese Medicines Authority to the company subsidiary, Avanti Rx Analytics.
Good morning. Good morning Irwin and Carl. Canopy usually leads the way as the sector bellwether (leading indicator) with the rest of the quality cannabis stocks following closely behind it. Directly versus our existing product. I just want to follow-up on the guidance question. If you look at our inventory, I think one of the things you will see is, there is a bit of a concentration on oils and we are actively working on managing all of the inventory balances, but that one in particular, some of our balances on salable flower were lower and that was where the customer demand was in the quarter.